NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2026)
NewAmsterdam Pharma's (NAMS) quarterly EBT Margin came in at 1593.45% in Q1 2026, down 26615.0% year-on-year from N/an in Q1 2025, and up 99.32% quarter-over-quarter from 234134.38% in Q4 2025.
NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has disclosed EBT Margin across 4 years of filings, most recently posting 1593.45% for Q1 2026.
- EBT Margin for Q1 2026 came in at 1593.45%, down 26615.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 942.76% (down 84278.0% YoY), and the FY2025 annual result was 905.74%, down 68326.0% from the prior year.
- EBT Margin came in at 1593.45% for Q1 2026 at NewAmsterdam Pharma, up from 234134.38% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 376.25% in Q4 2024 to a low of 234134.38% in Q4 2025.
- The 4-year median for EBT Margin is 1602.62% (2023), against an average of 21261.72%.
- Across the five-year window, EBT Margin soared 653665 bps in 2024 and plunged 23451063 bps in 2025, its largest moves.
- NewAmsterdam Pharma's EBT Margin stood at 6160.4% in 2023, then soared by 106 bps to 376.25% in 2024, then plunged by 62328 bps to 234134.38% in 2025, then surged by 99 bps to 1593.45% in 2026.
- The last three EBT Margin figures came in at 1593.45% (Q1 2026), 234134.38% (Q4 2025), and 20691.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - | -1,593.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,593.45% |
| Dec 31, 2025 | -234,134.38% |
| Sep 30, 2025 | -20,691.09% |
| Jun 30, 2025 | -90.70% |
| Mar 31, 2025 | -1,327.30% |
| Dec 31, 2024 | 376.25% |
| Sep 30, 2024 | -57.19% |
| Jun 30, 2024 | -1,711.58% |
| Mar 31, 2024 | -6,692.86% |
| Dec 31, 2023 | -6,160.40% |
| Sep 30, 2023 | -1,602.62% |
| Jun 30, 2023 | -2,230.11% |
| Mar 31, 2023 | -486.94% |